Specifically, a triplex vaccine containing the p185 target antigen combined with two powerful non-antigen-specific stimuli, IL-12 and allogeneic class I MHC molecules, was highly protective against mammary tumor onset in HER2 transgenic mice. This evidence concerns the gene ERBB2 and breast cancer.